OBJECTIVE: To determine how antiretroviral therapy (ART) or HAART affects the expression of apoptotic ligands and their death receptors in the blood and lymphoid tissues of HIV-infected patients and simian immunodeficiency virus-infected macaques. METHODS: We analyzed the mRNA expression of death molecules [tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and FasL] and their receptors (DR5 and Fas) in blood and tonsils from HIV-infected patients (HIV positive), HIV-infected patients receiving HAART and HIV-uninfected (HIV negative) donors in a cross-sectional study. We comparatively analyzed mRNA expression of TRAIL and DR5 in blood and lymph nodes collected longitudinally from simian immunodeficiency virus-infected macaques before and after ART. RESULTS: Expression of TRAIL, FasL, DR5 and Fas was elevated in circulating CD4 T cells from a group of HIV-positive patients as compared with that from both HIV-negative donors and HAART patients. In a different study group, TRAIL, FasL, DR5 and Fas were increased in tonsils of HIV-positive patients as compared with HIV-negative donors and HAART patients. However, tonsils from HAART patients showed reduced expression of TRAIL and FasL but not DR5 and Fas as compared with HIV-positive patients. Similarly, data obtained in a longitudinal study of simian immunodeficiency virus-infected macaques showed that ART reduced both TRAIL and DR5 in peripheral blood but only TRAIL and not DR5 in lymph nodes from the same animals. CONCLUSION: These findings suggest that HAART or ART is ineffective in reducing the expression of apoptotic death receptors in lymphoid tissue. However, analysis limited to blood leukocytes may not reveal such a defect. Our results highlight the persistence of an underlying immunologic condition that may prevent therapy-induced restoration of CD4 T cells in lymphoid tissue.
OBJECTIVE: To determine how antiretroviral therapy (ART) or HAART affects the expression of apoptotic ligands and their death receptors in the blood and lymphoid tissues of HIV-infectedpatients and simian immunodeficiency virus-infected macaques. METHODS: We analyzed the mRNA expression of death molecules [tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and FasL] and their receptors (DR5 and Fas) in blood and tonsils from HIV-infectedpatients (HIV positive), HIV-infectedpatients receiving HAART and HIV-uninfected (HIV negative) donors in a cross-sectional study. We comparatively analyzed mRNA expression of TRAIL and DR5 in blood and lymph nodes collected longitudinally from simian immunodeficiency virus-infected macaques before and after ART. RESULTS: Expression of TRAIL, FasL, DR5 and Fas was elevated in circulating CD4 T cells from a group of HIV-positivepatients as compared with that from both HIV-negative donors and HAART patients. In a different study group, TRAIL, FasL, DR5 and Fas were increased in tonsils of HIV-positivepatients as compared with HIV-negative donors and HAART patients. However, tonsils from HAART patients showed reduced expression of TRAIL and FasL but not DR5 and Fas as compared with HIV-positivepatients. Similarly, data obtained in a longitudinal study of simian immunodeficiency virus-infected macaques showed that ART reduced both TRAIL and DR5 in peripheral blood but only TRAIL and not DR5 in lymph nodes from the same animals. CONCLUSION: These findings suggest that HAART or ART is ineffective in reducing the expression of apoptotic death receptors in lymphoid tissue. However, analysis limited to blood leukocytes may not reveal such a defect. Our results highlight the persistence of an underlying immunologic condition that may prevent therapy-induced restoration of CD4 T cells in lymphoid tissue.
Authors: Y Mouton; S Alfandari; M Valette; F Cartier; P Dellamonica; G Humbert; J M Lang; P Massip; D Mechali; P Leclercq; J Modai; H Portier Journal: AIDS Date: 1997-10 Impact factor: 4.177
Authors: J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi Journal: Science Date: 1997-08-08 Impact factor: 47.728
Authors: Z Hel; D Venzon; M Poudyal; W P Tsai; L Giuliani; R Woodward; C Chougnet; G Shearer; J D Altman; D Watkins; N Bischofberger; A Abimiku; P Markham; J Tartaglia; G Franchini Journal: Nat Med Date: 2000-10 Impact factor: 53.440
Authors: Y Miura; N Misawa; N Maeda; Y Inagaki; Y Tanaka; M Ito; N Kayagaki; N Yamamoto; H Yagita; H Mizusawa; Y Koyanagi Journal: J Exp Med Date: 2001-03-05 Impact factor: 14.307
Authors: Constantinos Petrovas; David A Price; Joseph Mattapallil; David R Ambrozak; Christof Geldmacher; Valentina Cecchinato; Monica Vaccari; Elzbieta Tryniszewska; Emma Gostick; Mario Roederer; Daniel C Douek; Sara H Morgan; Simon J Davis; Genoveffa Franchini; Richard A Koup Journal: Blood Date: 2007-04-17 Impact factor: 22.113
Authors: Maristela Miyamoto; Silvana D Pessoa; Erika Ono; Daisy M Machado; Reinaldo Salomão; Regina C de M Succi; Savita Pahwa; Maria Isabel de Moraes-Pinto Journal: J Trop Pediatr Date: 2010-04-13 Impact factor: 1.165
Authors: Viskam Wijewardana; Adam C Soloff; Xiangdong Liu; Kevin N Brown; Simon M Barratt-Boyes Journal: PLoS Pathog Date: 2010-12-23 Impact factor: 6.823
Authors: Barbara Tavano; Rui Pedro Galao; David R Graham; Stuart J D Neil; Veronica N Aquino; Dietmar Fuchs; Adriano Boasso Journal: J Immunol Date: 2013-02-11 Impact factor: 5.422